openPR Logo
Press release

Irritable Bowel Syndrome (IBS) Treatment Market Size, Share, Trends and Forecast - 2025

07-15-2020 01:56 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Orion Market Research

IBS treatment Market

IBS treatment Market

The global irritable bowel syndrome (IBS) treatment market is projected to exhibit a significant growth, at a CAGR of around 9.5%, during the forecast period. The disturbance in the function of bowel leads to the occurrence of functional gastrointestinal disorder or say IBS. There are few medications available in the market that offer relief to the disorder. Along with the medications, there are several therapies being introduced in the IBS treatment market which are subjected to treat the syndrome. Stem cell therapy is one among those therapies that has been shown a significant relief in the condition of IBS. The increased understanding of the syndrome followed with immunopathology is aiding the development of new targeted treatment solutions for IBS, which includes the use of stem cell treatment, as they have a capability of modulating the immune system.

Get Sample Copy of Irritable Bowel Syndrome (IBS) Treatment Market at: https://www.omrglobal.com/request-sample/irritable-bowel-syndrome-ibs-treatment-market

The key players operating in the global IBS treatment market include Allergan PLC, Astellas Pharma, Inc., AstraZeneca PLC, Bausch Health Companies Inc., GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Co. Ltd.

The researchers of Copenhagen have reported the success in the IBS treatment in mice, via using its stem cells, to repair certain damage to the colon. The use of stem cell transplants for the treatment of immune systems has found to be successful in treating IBS. At present, there are two types of stem cells that are particularly used in the IBS treatment, namely, allogeneic stem cells and autologous stem cells. Among these two types, the allogeneic stem cells are considered more preferably over autologous stem cells for the IBS treatment. Allogeneic stem cells can be directly injected into the colon or infused through an IV drip.

In April 2019, Children’s Hospital of Fudan University in China offered a stem cell therapy to a newborn baby suffering with IBS. The hospital was successful in stem cell transplant of a baby in 2015, followed to which, the hospital decided to treat eight other children suffering with the same condition. The stem cell transplants were performed with relatively reduced chemotherapy condition, with an aim to lessen the toxicity of the process for the patients. Therefore, such successful stories related with the stem cell therapy in the treatment of IBS is further expected to propel the IBS treatment market growth during the forecast period.

For More Information, get A full report of Irritable Bowel Syndrome (IBS) Treatment Market is available at: https://www.omrglobal.com/industry-reports/irritable-bowel-syndrome-ibs-treatment-market

It is expected that the introduction of stem cell therapy in the treatment of irritable bowel syndrome will offer a chance to overturn the condition in patients dealing with mild, moderate or severe pain of IBS. Though, till date, the use of stem cell therapy has not received a wide FDA approval, and more of it is an experimental process. In addition, the use of stem cells in the IBS treatment entirely depends on the physician that have experienced with the use of allogeneic stem cells, through which, the IBS patients can achieve positive health outcomes.

Global IBS treatment Market-Segmentation

By Type

• IBS-Constipation
• IBS-Diarrhea
• IBS-Mixed
• IBS-Unsubtyped

By Drug Class

• Eluxadoline
• Linaclotide
• Lubiprostone
• Others (Rifaximin)

Global IBS treatment Market– Segment by Region

North America

• United States
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/irritable-bowel-syndrome-ibs-treatment-market

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Irritable Bowel Syndrome (IBS) Treatment Market Size, Share, Trends and Forecast - 2025 here

News-ID: 2090539 • Views:

More Releases from Orion Market Research

North American Cardiovascular Devices Market to Witness Growth Acceleration by 2031
North American Cardiovascular Devices Market to Witness Growth Acceleration by 2 …
North American cardiovascular devices market is projected to grow at a significant CAGR of 5.6% during the forecast period. The market growth in North America can be attributed to the rising geriatric population, frequent US FDA approvals for innovative cardiovascular devices, and the growing adoption of minimally invasive/non-invasive cardiac surgeries. There are several cardiac health organizations working in the US, such as American Heart Association. The geriatric population is more
Topical Drug Delivery Market Will Exhibit an Impressive Expansion by 2024-2031
Topical Drug Delivery Market Will Exhibit an Impressive Expansion by 2024-2031
The global topical drug delivery market is anticipated to grow at a considerable CAGR of 6.1% during the forecast period. The key factor contributing to the market growth includes the increasing approvals, grants, and clearance by government authorities and regulatory bodies for topical drugs. For instance, • In July 2022, Alembic Pharmaceuticals, (Aleor Dermaceuticals) received the US Food and Drug Administration (US FDA) approval for its Abbreviated New Drug Application (ANDA) for
Surgical Retractors Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Surgical Retractors Market Size, Trends, Latest Insights, Analysis and Forecast …
The global surgical retractors market is anticipated to grow at a considerable CAGR of 6.3% during the forecast period. The increasing research and development activities for the development of new and advanced medical devices by the pharmaceutical and biotechnology companies. Increasing demand for the new surgical devices by the end-users are key factors that are contributing to the growth of the surgical retractors market. For instance, • In June 2022, U.S.
Medical Packaging Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Medical Packaging Market Size, Trends, Latest Insights, Analysis and Forecast 20 …
The global medical packaging market is anticipated to grow with a significant CAGR of 6.1% during the forecast period. The growth of the medical packaging market is attributed to the rapidly changing healthcare industry. The medical packaging market is continuously experiencing various changes owing to the outbreak of new diseases, increasing regulatory norms, and growth in advanced healthcare systems. Furthermore, increasing development in diagnostics, pathological and other allied medical equipment

All 5 Releases


More Releases for IBS

Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide. A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning. This also includes consulting services concerning railway systems issues, such as travel
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011. The new bulkers, each with a capacity of 176,000 dwt, will be equipped
CoCoNet enhances MULTIVERSA IBS by OFTP access protocol
CoCoNet enhances the modern e-banking-platform MULTIVERSA IBS International Banking Server through an OFTP access channel (Odette File Transfer Protocol) for the data transmission between international banks and corporate customers. MULTIVERSA IBS is a modular and scalable platform for receiving and processing payment transaction data and delivering customer specific account information like account statements, intraday reports, returns and foreign exchange rate information. The initial situation at banks that now also offer